23andMe Investor Presentation Deck

Limited Use of Genetic Data and Lack of Patient Engagement Constrain Productivity 1. IND Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2. Probability of success for a drug to be approved is estimated to be <12%. 3. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). Drug Development is Inefficient 7 years average time-to-IND¹ $2.6B average cost of drug development³ Copyright © 2022 23and Me, Inc. ~90% failure rate2, 3 23andMe 26

View entire presentation